117 related articles for article (PubMed ID: 11942970)
1. Renal cell carcinoma may adapt to and overcome anti-angiogenic intervention with thalidomide.
Douglas ML; Reid JL; Hii SI; Jonsson JR; Nicol DL
BJU Int; 2002 Apr; 89(6):591-5. PubMed ID: 11942970
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma.
Myoung H; Hong SD; Kim YY; Hong SP; Kim MJ
Cancer Lett; 2001 Feb; 163(2):191-200. PubMed ID: 11165754
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition.
Kausch I; Jiang H; Ewerdwalbesloh N; Doehn C; Krüger S; Sczakiel G; Jocham D
BJU Int; 2005 Feb; 95(3):416-20. PubMed ID: 15679806
[TBL] [Abstract][Full Text] [Related]
4. [Interest of color Doppler ultrasonography to evaluate a new anti-angiogenic treatment with thalidomide in metastatic renal cell carcinoma].
Lassau N; Chawi I; Rouffiac V; Bidault S; Escudier B; Leclère J
Bull Cancer; 2004; 91(7-8):629-35. PubMed ID: 15381453
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic therapy in renal cell cancer.
Srinivasan R; Armstrong AJ; Dahut W; George DJ
BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
[TBL] [Abstract][Full Text] [Related]
6. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
[TBL] [Abstract][Full Text] [Related]
7. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy.
Saylor PJ; Escudier B; Michaelson MD
Clin Genitourin Cancer; 2012 Jun; 10(2):77-83. PubMed ID: 22382009
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice.
Kotoh T; Dhar DK; Masunaga R; Tabara H; Tachibana M; Kubota H; Kohno H; Nagasue N
Surgery; 1999 May; 125(5):536-44. PubMed ID: 10330943
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
Sawhney R; Kabbinavar F
Curr Urol Rep; 2008 Jan; 9(1):26-33. PubMed ID: 18366971
[TBL] [Abstract][Full Text] [Related]
10. [Effect of thalidomide on tumor growth in mouse hepatoma H22 model].
Zhai Y; Lu ZJ
Ai Zheng; 2003 Dec; 22(12):1301-6. PubMed ID: 14693056
[TBL] [Abstract][Full Text] [Related]
11. Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma.
Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M
J Urol; 2004 Feb; 171(2 Pt 1):897-902. PubMed ID: 14713849
[TBL] [Abstract][Full Text] [Related]
12. Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma.
Hii SI; Nicol DL; Gotley DC; Thompson LC; Green MK; Jonsson JR
Br J Cancer; 1998 Mar; 77(6):880-3. PubMed ID: 9528828
[TBL] [Abstract][Full Text] [Related]
13. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines.
Grepin R; Guyot M; Jacquin M; Durivault J; Chamorey E; Sudaka A; Serdjebi C; Lacarelle B; Scoazec JY; Negrier S; Simonnet H; Pages G
Oncogene; 2012 Mar; 31(13):1683-94. PubMed ID: 21909141
[TBL] [Abstract][Full Text] [Related]
14. Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice.
Coltrini D; Ronca R; Belleri M; Zardi L; Indraccolo S; Scarlato V; Giavazzi R; Presta M
J Pathol; 2009 Dec; 219(4):455-62. PubMed ID: 19824060
[TBL] [Abstract][Full Text] [Related]
15. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma.
Daliani DD; Papandreou CN; Thall PF; Wang X; Perez C; Oliva R; Pagliaro L; Amato R
Cancer; 2002 Aug; 95(4):758-65. PubMed ID: 12209719
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin-like growth factor binding protein-3 levels.
Cheung CW; Taylor PJ; Kirkpatrick CM; Vesey DA; Gobe GC; Winterford C; Nicol DL; Johnson DW
BJU Int; 2007 Aug; 100(2):438-44. PubMed ID: 17617146
[TBL] [Abstract][Full Text] [Related]
17. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
18. Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.
Jeong DE; Song HJ; Lim S; Lee SJ; Lim JE; Nam DH; Joo KM; Jeong BC; Jeon SS; Choi HY; Lee HW
Oncotarget; 2015 Oct; 6(32):33046-64. PubMed ID: 26426994
[TBL] [Abstract][Full Text] [Related]
19. Tubulogenesis by microvascular endothelial cells is mediated by vascular endothelial growth factor (VEGF) in renal cell carcinoma.
Nakagawa M; Emoto A; Hanada T; Nasu N; Nomura Y
Br J Urol; 1997 May; 79(5):681-7. PubMed ID: 9158500
[TBL] [Abstract][Full Text] [Related]
20. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
Li H; Raia V; Bertolini F; Price DK; Figg WD
BJU Int; 2008 Apr; 101(7):884-8. PubMed ID: 18070197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
